Page last updated: 2024-11-04

1-(5-isoquinolinesulfonyl)-2-methylpiperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3542
CHEMBL ID323556
CHEBI ID43385
CHEBI ID83438
SCHEMBL ID190590
MeSH IDM0028749

Synonyms (88)

Synonym
5-[(2-methylpiperazin-1-yl)sulfonyl]isoquinoline
CHEMBL323556 ,
brd6846
BRD-A55756846-001-05-5
brd-6846
SGCUT00137
BIO2_000863
BIO1_000920
BIO1_001409
BIO1_000431
BIO2_000383
BSPBIO_001105
LOPAC0_000598
BIOMOLKI2_000014
IDI1_002138
BIOMOLKI_000004
SMP2_000201
brn 5482740
piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-, (2s-(1(r*(r*)), 2alpha, 3abeta, 7abeta))-
MLS001332489
MLS001332490
1-5-isoquinolinesulphonyl-2-methylpiperazine
piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-
5-(2-methylpiperazin-1-yl)sulfonylisoquinoline
h-7
piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-, (2s-(1(r*(r*)),2alpha,3abeta,7abeta))-
h 7
isoquinoline-5-sulfonic 2-methyl-1-piperazide
protein kinase inhibitor h7
1-(5-isoquinolinylsulfonyl)-2-methylpiperazine
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
84477-87-2
piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl- (9ci)
TO_000063
LOPAC0_000682
NCGC00024640-04
NCGC00024640-05
smr000058749
MLS000069615 ,
KBIO2_005581
KBIO3_000829
KBIO2_003013
KBIO3_000830
KBIOGR_000445
KBIOSS_000445
KBIO2_000445
NCGC00024640-06
NCGC00024640-03
5-(2-methylpiperazine-1-sulfonyl)isoquinoline
CHEBI:43385 ,
HMS1990G07
NCGC00015487-11
DB07996
HMS1362G07
HMS1792G07
bdbm50216682
cid_3542
AKOS009159179
487h9q0f9n ,
unii-487h9q0f9n
HMS2231B22
CCG-100608
NCGC00015487-07
NCGC00015487-12
NCGC00015487-08
NCGC00015487-09
NCGC00015487-05
NCGC00015487-06
HMS3374N04
SCHEMBL190590
(+/-)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine
CHEBI:83438
HMS3403G07
OPERA_ID_1708
1-(5-isoquinolinylsulfonyl)-2-methyl-piperazine
FT-0757321
h-7 inhibitor
EX-A7026
5-((2-methylpiperazin-1-yl)sulfonyl)isoquinoline ,
BRD-A55756846-300-01-0
SDCCGSBI-0050580.P003
NCGC00015487-16
MS-24163
DTXSID401004756
protein kinase inhibitor h-7
HY-131900
CS-0142529
GLXC-26402

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Signal transduction systems that modulate protein kinase C (PKC) also can modulate the toxic effects of anoxia and NO."( Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C.
Boccone, L; Maiese, K, 1995
)
0.29
" We examined in primary cultured hippocampal neurons whether the protein kinases PKC, PKA, CaM-II, and cGMP-dependent protein kinase modified the toxic effects of anoxia and NO."( Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia.
Boniece, IR; Maiese, K; Skurat, K; Wagner, JA, 1993
)
0.29
" In this review, we are introducing our new less-invasive intrathecal drug delivery system that provides an alternative and safe method to deliver therapeutic agents."( Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil.
Ishida, T; Kiwada, H; Takanashi, Y, 2006
)
0.33
" The occurrence of adverse events, occurrence of low density areas associated with vasospasm on computed tomography, absence of symptomatic vasospasm, and poor clinical outcomes associated with vasospasm were compared between the fasudil and fasudil plus ozagrel groups."( Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study.
Satoh, S; Seto, M; Shibuya, M; Sugiyama, H; Suzuki, Y; Takakura, K, 2008
)
0.35
" Symptomatic vasospasm, low density areas on computed tomography (CT), clinical outcomes, and adverse events were all recorded, and the results were compared between the fasudil and nimodipine groups."( Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011
)
0.37
" The aim of this study was to evaluate the anti-MPD activity of a clinically safe drug, Fasudil, identified in an in vitro kinase inhibitor as an inhibitor of proliferation of DKO mouse hematopoietic stem/progenitor cells (HSPCs)."( Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
An, W; Band, H; Band, V; Feng, D; Mohapatra, BC; Nadeau, S; Storck, MA; William, BM, 2016
)
0.43
"Our results suggest a therapeutic potential for fasudil, a clinically safe drug with promising results in vascular diseases, in the treatment of MPDs or other mutant Cbl-driven myeloid disorders."( Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
An, W; Band, H; Band, V; Feng, D; Mohapatra, BC; Nadeau, S; Storck, MA; William, BM, 2016
)
0.43
" In the brains of Alzheimer's disease sufferers, amyloid β (Aβ) peptides aggregate to form senile plaques but as soluble peptides are toxic to synapses."( Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil.
Al-Shawi, R; Baillie, G; Cuadrado, A; Elliott, C; Ghosh, A; Harte, M; Hooper, NM; Jackson, J; Jarosz-Griffiths, HH; Killick, R; Lovestone, S; Morin, P; Porter, R; Preston, J; Ribe, E; Rojo, AI; Sellers, KJ; Semenov, M; Simons, P; Srivastava, DP; Watson, IA; Xia, W, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study aimed to determine the protective effect of fasudil pretreatment combined with IPO on myocardial ischemia/reperfusion injury in rats and explore the possible mechanisms."( The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats.
Guan, YE; Jia, DL; Li, WN; Shu, WQ; Wu, N, 2014
)
0.4
"Present study was conducted to investigate the effects of rosuvastatin combined with fasudil on rabbits with dyslipidemia."( Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia.
Li, Z; Lian, H; Liang, Q; Zeng, F; Zheng, D, 2015
)
0.42
"Rosuvastatin combined with fasudil conferred synergistic effects on endothelium-protection and inflammation- and oxidation-amelioration in the setting of early stage of dyslipidemia."( Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia.
Li, Z; Lian, H; Liang, Q; Zeng, F; Zheng, D, 2015
)
0.42
" In the current study, we observed the therapeutic potential of MSCs combined with Fasudil in mouse model of experimental autoimmune encephalomyelitis (EAE) and explored possible mechanisms of action."( Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis.
Li, YH; Liu, CY; Liu, JC; Ma, CG; Song, GB; Wang, Q; Xiao, BG; Yan, YP; Yang, WF; Yu, JW; Yu, JZ; Zhang, HF, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"Investigations from basic biology suggest that activation of the Rho/Rho kinase pathway reduces the bioavailability of nitric oxide (NO) and thereby promotes atherosclerosis and its clinical complications."( Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.
Creager, MA; Ganz, P; Grunert, ME; Liao, JK; Nohria, A; Noma, K; Prsic, A; Rikitake, Y, 2006
)
0.33
"Taken together, these results first suggest that the effect of physical activity on the FST is dependent on either the increase in the bioavailability of monoamines in the synaptic cleft or an activation of intracellular signaling pathways mediated by PKA and CAMK-II."( The antidepressant-like effect of physical activity on a voluntary running wheel.
Aguiar, AS; Bettio, LE; Budni, J; Cunha, MP; Machado, DG; Martins, DF; Oliveira, Á; Pazini, FL; Rodrigues, AL; Santos, AR, 2013
)
0.39
"Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome."( Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016
)
0.43
" Considering increased ROCK activity contribution to progression of PAH, ROCK inhibition influences NO bioavailability through RBC eNOS, in addition to endothelial eNOS."( Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil.
Basarici, I; Basrali, F; Celik, ML; Kilavuz, E; Kısak, F; Koksoy, S; Özen, N; Ulker, P; Yaras, N, 2020
)
0.56
" All 21 drugs are orally bioavailable or topically effective."( Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski, R, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Depletion of PKC by prolonged incubation with phorbol esters also inhibited phagocytosis, and dose-response curves showed a strong correlation between the extent of PKC depletion and the extent of inhibition of ingestion."( Immunoglobulin-mediated phagocytosis by human monocytes requires protein kinase C activation. Evidence for protein kinase C translocation to phagosomes.
Brown, EJ; Zheleznyak, A, 1992
)
0.28
" The dose-response of [3H]thymidine incorporation induced by IGF-I and TPA indicated that 10 nM was the lowest concentration producing a maximal effect for both agents."( Involvement of protein kinase-C in the mitogenic effect of insulin-like growth factor-I on rat astrocytes.
Calle, R; Naftolin, F; Robbins, R; Tranque, PA, 1992
)
0.28
" Dose-response curves demonstrated that H-7 is the most effective among the inhibitors, and the transepithelial resistance was 70% of control up to 1 h after calcium removal."( Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells.
Citi, S, 1992
)
0.28
" With the intracellular delivery of the inhibitor(s) beginning 30 min before the tetanus, PMB in adequate dosage or a combination of PMB and PKC-(19-31), each at a low dosage, could block the development of LTP completely including its initial induction phase."( Postsynaptic protein kinase C essential to induction and maintenance of long-term potentiation in the hippocampal CA1 region.
Feng, DP; Wang, JH, 1992
)
0.28
" Time-course kinetics and dose-response curves of RNA and DNA synthesis induced by bryostatin 1 or PMA were comparable, albeit the phorbol ester was significantly more potent."( Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation.
Drexler, HG; Gignac, SM; Hoffbrand, AV; Pettit, GR, 1990
)
0.28
" Thus, the effects of HA1077 on neurotransmitter metabolism are complex and vary depending on the dosage and sites of the brain."( Effects of HA1077, an intracellular calcium antagonist, on neurotransmitter metabolism in rat brain in vivo.
Kondoh, Y; Mizusawa, S; Murakami, M; Nagata, K; Nakamichi, H; Watanabe, K, 1991
)
0.28
" The dose-response relation with AVP thus shifted to the right."( Inhibition by phorbol ester of cellular adenosine 3',5'-monophosphate production and cellular free calcium mobilization in response to arginine vasopressin in rat renal papillary collecting tubule cells in culture.
Ishikawa, S; Saito, T, 1991
)
0.28
" The dose-response curve of HA1077 for MLC20 phosphorylation was to the left of the tension curve produced by 40 mM K+."( Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle.
Hidaka, H; Sasaki, Y; Seto, M, 1991
)
0.28
" H-7 produced a shift to the right of the dose-response curve for the PKC activator, 12-o-tetradecanoylphorbol-13-acetate (TPA) in the case of SHR aortas, while no such shift was noted in tissues from WKY."( Effects of H-7 (protein kinase inhibitor) and phorbol ester on aortic strips from spontaneously hypertensive rats.
Iwasaki, T; Miyata, S; Morita, S; Nagai, K; Shibata, R, 1990
)
0.28
" Protein kinase inhibitors block v-Src- and v-Fps-induced 9E3 gene expression with the same dose-response curves seen for PKC agonist-induced 9E3 gene expression."( Evidence that v-src and v-fps gene products use a protein kinase C-mediated pathway to induce expression of a transformation-related gene.
Berg, KL; Foster, DA; Joseph, C; Qureshi, SA; Spangler, R, 1989
)
0.28
" Dose-response curves for ET-1 relaxation were shifted to the left."( Two receptor subtypes are involved in the contractile component of the guinea pig ileum responses to endothelins.
Ihara, M; Miasiro, N; Paiva, AC; Yano, M, 1993
)
0.29
" Octanol produced a shift of the current dose-response curve toward lower concentrations of GABA."( Selective effects of alcohols on gamma-aminobutyric acid A receptor subunits expressed in human embryonic kidney cells.
Carter, DB; Hamilton, BJ; Kurata, Y; Marszalec, W; Narahashi, T, 1994
)
0.29
" Desensitization of the somatostatin response involved a shift in its dose-response curve toward higher somatostatin concentrations as well as a decrease in the maximal response."( Substance P potentiates calcium channel modulation by somatostatin in chick sympathetic ganglia.
Golard, A; Role, L; Siegelbaum, SA, 1994
)
0.29
" The dose-response and the time-course of the inhibitor, however, indicated that the site of action of TPCK for NF-kappa B activation and for DNA fragmentation are quite distinct."( Protease inhibitors differentially regulate tumor necrosis factor-induced apoptosis, nuclear factor-kappa B activation, cytotoxicity, and differentiation.
Aggarwal, BB; Chan, H; Higuchi, M; Singh, S, 1995
)
0.29
" The dose-response curves defining the TPA-dependent suppression of EROD induction and PKC down-regulation were very similar, as were the initial kinetics of PKC loss and the times of TPA pretreatment required for suppression of EROD induction."( Suppression of cytochrome P450 Cyp1a-1 induction in murine hepatoma 1c1c7 cells by 12-O-tetradecanoylphorbol-13-acetate and inhibitors of protein kinase C.
Bischer, P; Cantu, AR; Pavone, A; Reiners, JJ; Schöller, A, 1993
)
0.29
" Staurosporin potentiated Ca(2+)-induced Peth formation by shifting the [Ca2+]cyt dose-response curve to the left."( The role of cytosolic Ca2+, protein kinase C, and protein kinase A in hormonal stimulation of phospholipase D in rat hepatocytes.
Benistant, C; Gustavsson, L; Hoek, JB; Moehren, G; Rubin, R; Torres-Marquez, ME, 1994
)
0.29
" External H-7 shifted the dose-response curve of GABA-activated currents downward without changing the EC50 significantly (from 15."( Modulation of nicotinic ACh-, GABAA- and 5-HT3-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones.
Hu, HZ; Li, ZW, 1997
)
0.3
" Dose-response curves to the hormone were determined in the absence and in the presence of several drugs that affect sequential steps of the Ca(2+)-dependent signalling pathway."( Cellular signalling of PCH-induced pigment aggregation in the crustacean Macrobrachium potiuna erythrophores.
Castrucci, AM; da Silva, MA; Josefsson, L; Nery, LE, 1997
)
0.3
" The ACh dose-response curve was shifted to the left and to the right after treatment with 1 and 100 microM MeAMPH, respectively, suggesting that MeAMPH potentiated or inhibited ACh-evoked currents by a change in the affinity for ACh."( Methamphetamine modulates ACh-evoked currents in Xenopus occytes expressing the rat alpha7 receptors.
Nishizaki, T; Nomura, T, 1997
)
0.3
"Cellular contraction was observed with ethacrynic acid, colchicine, and vinblastine in the 10(-5) to 10(-4) M dosage range."( Microtubule disruption leads to cellular contraction in human trabecular meshwork cells.
Epstein, DL; Gills, JP; Roberts, BC, 1998
)
0.3
" Imipramine increased the maximum response to 5-HT without altering the EC50 of the dose-response curve."( Chronic imipramine administration amplifies the serotonin2A receptor-induced intracellular Ca2+ mobilization in C6 glioma cells through a calmodulin-dependent pathway.
Kamei, K; Muneoka, K; Muraoka, S; Takigawa, M, 1998
)
0.3
" Comparison of the dose-response curves between TPA-induced hydrogen (H+) secretion, as measured by aminopyrine (AP) uptake, and the membrane-associated PKC-alpha suggests that translocation of PKC-alpha is not involved in the H+ secretory process in PC."( Expression and characterization of protein kinase C in isolated rabbit parietal cells.
Kim, SW; Levine, RA; Loo, A; Nandi, J, 1999
)
0.3
" The dose-response curves for ATP4- show that IBaL and IBaN proportionally increased with ATP4- concentrations up to 1 mM at three different Mg2+ concentrations."( Regulation of L- and N-types of Ca2+ channels by intracellular ATP4- in frog dorsal root ganglion neurons.
Seyama, I; Yamaoka, K; Yuki, T, 1999
)
0.3
" Rightward shift of the dose-response curves due to coinfusion of inhibitors served to assess contribution of different pathways: trimethoxybenzoate (TMB-8) against Ca2+ mobilization, nifedipine against Ca2+ influx, staurosporine and Ro-318220 against PKC, and Y-27632 and HA-1077 against ROK."( Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat.
Bauer, J; Parekh, N, 2003
)
0.32
" They shifted dose-response curves of Ang II, norepinephrine, and AVP to sevenfold and higher values."( Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat.
Bauer, J; Parekh, N, 2003
)
0.32
" Higher baseline IOP and repeated dosing were associated with greater IOP reduction."( Effects of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys.
Kaufman, PL; Podos, SM; Tian, B; Wang, RF, 2004
)
0.32
" There is no dosage and time dependence of PKC inhibitor in regulating eosinophil apoptosis of nasal polyps."( [The influence of protein kinase C inhibitor in eosinophil apoptosis of nasal polyps].
Li, MH; Yang, ZQ; Yin, WZ, 2004
)
0.32
" Injection of 10 microM and 100 microM Y-27632 induced extension of the optic axons beyond the crush site, with the latter dosage giving stronger regeneration."( Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats.
Ichikawa, M; Sagawa, H; Saito, K; Tokita, Y; Watanabe, M; Yoshida, J, 2008
)
0.35
" Multiple daily dosing with the drug produced a persistent IOP-lowering effect."( Evaluation of monkey intraocular pressure by rebound tonometer.
Cao, G; Chen, L; Li, N; Liu, X; Ma, J; Pang, IH; Qiu, J; Yan, N; Yu, M; Yu, W, 2009
)
0.35
" Moreover, fasudil pretreatment shifted norepinephrine dose-response curves to the right more in WKY than in SHR."( Ca2+ sensitization and Ca2+ entry in the control of blood pressure and adrenergic vasoconstriction in conscious Wistar-Kyoto and spontaneously hypertensive rats.
Behuliak, M; Bencze, M; Karen, P; Kuneš, J; Líšková, S; Petrová, M; Pintérová, M; Vaněčková, I; Zicha, J, 2013
)
0.39
" ST21-H3R5-polyethylene glycol (PEG) exhibited excellent loading capacities for both fasudil and miR195 with adjustable dosing ratios."( Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
Gao, Y; Gu, S; Li, X; Liu, G; Liu, Y; Wu, X; Zhang, D; Zhang, J; Zhu, G, 2016
)
0.43
" Overall, CAR-modified-liposomes of SOD plus fasudil, given every 72 h, was as efficacious as plain drugs, given every 48 h, suggesting that the formulation can reduce the total drug intake, systemic exposures, and dosing frequency."( Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Ahsan, F; Gupta, N; McMurtry, IF; Nozik-Grayck, E; Rashid, J; Stenmark, KR, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 2.7.11.13 (protein kinase C) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
EC 2.7.11.13 (protein kinase C) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
N-sulfonylpiperazine
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
N-sulfonylpiperazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency56.23410.003245.467312,589.2998AID2517
thioredoxin reductaseRattus norvegicus (Norway rat)Potency50.11870.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency8.52690.004110.890331.5287AID493106; AID493107; AID504467
GLS proteinHomo sapiens (human)Potency14.12540.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency32.68560.000811.382244.6684AID686978; AID686979
regulator of G-protein signaling 4Homo sapiens (human)Potency8.42880.531815.435837.6858AID504845
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency18.47820.819914.830644.6684AID720572; AID720573
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency16.36010.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency24.45300.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
huntingtin isoform 2Homo sapiens (human)Potency10.00000.000618.41981,122.0200AID1688
ras-related protein Rab-9AHomo sapiens (human)Potency100.00000.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency16.84000.00378.618923.2809AID2667; AID2668
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency8.91250.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency8.91250.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency8.91250.15855.287912.5893AID540303
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
D(1A) dopamine receptorSus scrofa (pig)Potency23.28090.00378.108123.2809AID2667
Ataxin-2Homo sapiens (human)Potency22.38720.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,322)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990279 (8.40)18.7374
1990's1666 (50.15)18.2507
2000's675 (20.32)29.6817
2010's618 (18.60)24.3611
2020's84 (2.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 6.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index6.95 (24.57)
Research Supply Index8.15 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (6.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials41 (1.20%)5.53%
Reviews81 (2.37%)6.00%
Case Studies10 (0.29%)4.05%
Observational0 (0.00%)0.25%
Other3,280 (96.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD) [NCT05931575]Phase 275 participants (Anticipated)Interventional2023-09-11Recruiting
A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost [NCT04793659]Phase 224 participants (Actual)Interventional2020-12-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]